4th Quarter Report

Fourth Quarter 2019 Report

January 20, 2020

Click Image to view a larger version in New Tab

OneTest Quarterly Test Revenue More than Doubles; International Sales Added

For the 3 month period ending December 31, our cancer test revenue more than doubled over the revenue generated in the previous Quarter. Additionally, we saw for the first time, revenue generating activity overseas using our cloud portal. We anticipate continuing this growth trajectory throughout the current calendar year as we have a pipeline of quote requests for several thousand tests from occupational health groups throughout the U.S.

Further information about OneTest™ may be found here.

New Financing Round Underway

Last month, our Series C Financing Round was Qualified by the SEC under Regulation A+. A copy of our Offering Circular may be downloaded here. We are seeking at least $10 million from a combination of retail (crowd) investors, along with institutional investors

We are now raising capital on the StartEngine crowdfunding portal. The 20/20 campaign page may be accessed at www.startengine.com/2020-gene-systems .

Please consider investing today and share this link with others in your network!

20/20 Admitted to Elite Ping An Business Accelerator in China

20/20 has been selected to be part of the next cohort of companies admitted to the Ping An Cloud Accelerator in Shenzhen China. Fewer than 3% of applicant companies are accepted into this China market-focused program that catalyzes alliances with various Ping An business units including PingAn Health and Ping An Good Doctor. A press release announcing 20/20's selection may be downloaded here. Of the 11 companies selected in this cohort we are one of only two from the U.S.

20/20's inclusion into this ultra-competitive 5-month program followed a successful review of our technology and business model by Ping An Health's diagnostic testing laboratory division.

Ping An is a digital healthcare powerhouse, ranked #29 on the Fortune 500 Global list, with over 300 million customers in China. A feature story discussing Ping An's leadership in big data and AI appeared last July in Fortune magazine and may be accessed here.

In 2016, Ping An invested $2 million in 20/20. They have a seat on our Board of Directors.

OneTest Algorithm Re-Validated on Large Independent Chinese Data Set

Throughout East Asia, most adults receive blood tests for many tumor markers that are part of OneTest as part of yearly health examinations. Hospitals in major cities such as Chongqing run hundreds of such blood test every day!

Last month we conducted a study to further validate the power of the OneTest machine learning algorithm to improve the accuracy of these commonly tested biomarkers. Using a cohort of about 150,000 individuals tested in 2018 at Chongqing Medical University, our current algorithm correctly identified 75% more cancers than with standard methods. Further collaborations with this respected medical center are planned this year to further improve the OneTest algorithm.

Scientific Leader Returns to 20/20

Michael Lebowitz, Ph.D., formerly Director of R&D at 20/20 from 2009 through 2012, has returned to the company as Chief Scientific Officer. Dr. Lebowitz is a biotech professional with >25 years research experience including 20+ years with companies focused on developing cancer diagnostics and/or therapies of which more than 15 years were in research management.

During his previous tenure with 20/20 he completed the development and commercial launch of our PAULAs test for the early detection of lung cancer and managed the establishment and oversight of our CLIA laboratory.

For more than a decade Michael has been an Adjunct Professor at Johns Hopkins University teaching graduate level classes in biochemistry and cell biology. Previsouly at Johns Hopkins he earned his Ph.D.in the Biochemistry, Cellular and Molecular Biology program.

Recruit Your Healthcare Provider & Get Free Yearly Cancer Screening for Life

Because of our success last year with equity crowdfunding under the new Regulation A+, 20/20 is fortunate to have over 4,000 shareholders throughout the U.S. and around the world. We are now seeking to leverage this substantial shareholder base to help grow test adoption worldwide.

We invite all shareholders to introduce OneTest to their doctor or medical screening provider. (We will provide you with a short hand-out to present to your doctor that summarizes the test's clinical performance and value.) If your introduction results in the healthcare provider routinely offering this test to patients, you will be entitled to a yearly OneTest™ for the rest of your life at no cost. (Available to US shareholders only)

For details, please contact Careen at ccarlton@2020gene.com or call 240-453-6339 x 108

Our previous Quarterly Reports may be downloaded here:

Financial Reports

In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those interested in obtaining copies of recently SEC filed Financial Statements should contact DavidK@2020gene.com

Regulation A Offering and Forward Looking Statements

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.

THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE .

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.